Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell ...

Highlighting Positive Results in Comparison to Valchlor(R) and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Nate, 55, a smoker, has seen three dermatologists for a rash that seems to be resistant to various treatments. He has complained that he has had a chronic bumpy and painful rash with pustules ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least ...

PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with ...

Tattoos may increase the risk of developing lymphoma and skin cancer, a recent study suggests. "We can see that ink particles accumulate in the lymph nodes, and we suspect that the body perceives them ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...